Another experimental monoclonal antibody has shown promise in treating early Alzheimer’s disease, with Eli Lilly announcing its candidate can slow cognitive decline by a third…
Patients recently diagnosed with dementia are at increased risk of self-harm, especially within the first 6-12 months of diagnosis, a large Australian study shows. Those…
Cardiovascular disease risk modification may be critical to preventing adults with focal epilepsy from developing dementia in later life, UK doctors report. The advice follows…
Billions of dollars in research. Hundreds of failed experiments. Half a dozen competing theories. The search for an effective dementia treatment has proven expensive and…
Elite male soccer players are 60% more likely to develop Alzheimer’s disease or other dementias compared with the general population, a study shows. But goalkeepers do…
Doctors have successfully adapted a widely used cognitive screening test to make it suitable for patients with hearing loss emphasising written instructions rather than spoken…
The US Food and Drug Administration has approved a second drug for Alzheimer’s disease, lecanemab (Leqembi), despite reports of rare brain bleeds linked to use…
“Impressive”. “Remarkable”. “Game-changing”. There was no shortage of praise for the experimental dementia drug lecanemab following the release of phase III trial results late last year. The study,…
Improving anxiety symptoms in older adults using psychotherapy is associated with significant long-term reductions in dementia risk, shows a large real-world study. Analysis of data…
For individuals with hearing loss, use of hearing aid devices is associated with a reduced risk for long-term cognitive decline, according to a review published…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.
